Latest & greatest articles for brimonidine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on brimonidine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on brimonidine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for brimonidine

1. Brimonidine

Brimonidine Top results for brimonidine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for brimonidine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin

Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin - GOV.UK GOV.UK uses cookies to make the site simpler. Search Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin Systemic cardiovascular effects including bradycardia, hypotension, and dizziness have been reported after application (...) . It is important to avoid application to irritated or damaged skin, including after laser therapy. Published 21 June 2017 From: Therapeutic area: , Advice for healthcare professionals: cases of bradycardia, hypotension (including orthostatic hypotension), and dizziness after application of brimonidine gel have been reported, some of which required hospitalisation some cases were associated with application of brimonidine gel after laser procedures to the skin, which possibly caused increased absorption

2017 MHRA Drug Safety Update

3. Brimonidine gel (Mirvaso): risk of exacerbation of rosacea

Brimonidine gel (Mirvaso): risk of exacerbation of rosacea Brimonidine gel (Mirvaso): risk of exacerbation of rosacea - GOV.UK GOV.UK uses cookies to make the site simpler. Search Brimonidine gel (Mirvaso): risk of exacerbation of rosacea Some patients may have exacerbation or rebound symptoms of rosacea. It is important to initiate treatment with a small amount of gel and increase the dose gradually, based on tolerability and treatment response. Published 8 November 2016 From: Therapeutic area (...) : Contents Advice for healthcare professionals: exacerbation of rosacea symptoms occurred in up to 16% of patients treated with brimonidine gel in clinical studies; in most cases, erythema and flushing resolve after stopping treatment initiate treatment with a small amount of gel (less than the maximum dose) for at least 1 week and increase the dose gradually, based on tolerability and response to treatment advise patients carefully on how to apply the gel and on the importance of not exceeding

2016 MHRA Drug Safety Update

4. Brimonidine (Mirvaso®)

Brimonidine (Mirvaso®) Brimonidine (Mirvaso®) Brimonidine (Mirvaso®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Brimonidine (Mirvaso®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 2168. 2015 Authors' conclusions Brimonidine (Mirvaso®) is recommended for restricted use within NHS Wales for the symptomatic treatment of facial erythema of rosacea in adult patients. Brimonidine (Mirvaso®) should be restricted for use in patients with moderate to severe persistent facial erythema associated with rosacea. Brimonidine (Mirvaso®) is not recommended for use within NHS Wales outside of this subpopulation. Final publication URL Indexing Status Subject

2015 Health Technology Assessment (HTA) Database.

5. Brimonidine (Mirvaso) - for the symptomatic treatment of facial erythema of rosacea

Brimonidine (Mirvaso) - for the symptomatic treatment of facial erythema of rosacea Final Appraisal Recommendation Advice No: 2015 – July 2015 Brimonidine (Mirvaso ® ) 3 mg/g gel Submission by Galderma (UK) Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2168), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company’s (...) : brimonidine (Mirvaso ® ) 3 mg/g gel. July 2015. Recommendation of AWMSG Brimonidine (Mirvaso ® ) is recommended for restricted use within NHS Wales for the symptomatic treatment of facial erythema of rosacea in adult patients. Brimonidine (Mirvaso ® ) should be restricted for use in patients with moderate to severe persistent facial erythema associated with rosacea. Brimonidine (Mirvaso ® ) is not recommended for use within NHS Wales outside of this subpopulation.

2015 All Wales Medicines Strategy Group

6. Glaucoma: brinzolamide/brimonidine combination eye drops

Glaucoma: brinzolamide/brimonidine combination eye drops Glaucoma: brinzolamide/brimonidine Glaucoma: brinzolamide/brimonidine combination e combination ey ye drops e drops Evidence summary Published: 17 March 2015 nice.org.uk/guidance/esnm56 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in March 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up (...) -to-date information. Summary In 2 randomised controlled trials in people with glaucoma, brinzolamide/brimonidine combination eye drops were statistically significantly superior to either constituent drug administered alone as monotherapy in reducing intraocular pressure at 3 months. The combination eye drops were non-inferior to brinzolamide plus brimonidine administered concomitantly. Most reported adverse events were mild to moderate and localised, but these were higher in number

2015 National Institute for Health and Clinical Excellence - Advice

7. Facial erythema of rosacea: brimonidine tartrate gel

Facial erythema of rosacea: brimonidine tartrate gel Facial erythema of rosacea: brimonidine tartr Facial erythema of rosacea: brimonidine tartrate ate gel gel Evidence summary Published: 8 July 2014 nice.org.uk/guidance/esnm43 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in July 2014. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date (...) information. Summary In 2 short-term randomised controlled trials (RCTs: n=553) brimonidine tartrate gel was statistically significantly more effective than vehicle gel in reducing erythema in people with a clinical diagnosis of rosacea and moderate to severe erythema. However, 'success rates' (defined as a 2-grade reduction in the severity of erythema as assessed by both patients and clinicians) were just 25% to 30% with brimonidine gel compared with about 10% for vehicle gel at day 29. © NICE 2018. All

2014 National Institute for Health and Clinical Excellence - Advice

8. Simbrinza - brinzolamide / brimonidine tartrate

Simbrinza - brinzolamide / brimonidine tartrate 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu 22 May 2014 EMA/366328/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Simbrinza International non-proprietary name: Brinzolamide / Brimonidine tartrate Procedure No. EMEA/H/C/003698/0000 Note Assessment report (...) 73 2.6.1. Discussion on clinical safety 74 2.6.2. Conclusions on the clinical safety 76 2.7. Pharmacovigilance 77 2.8. Risk Management Plan 77 2.9. User consultation 78 3. Benefit-Risk Balance 79 4. Recommendations 83 Assessment report EMA/366328/2014 Page 4/83 List of abbreviations Abbreviation/Term Definition a2 Alpha 2 ADR Adverse drug reaction AE Adverse event AUC Area under the curve BAK Benzalkonium chloride BID Two times daily (Bis in Die) Brinz/Brim Brinzolamide /Brimonidine 10mg/mL + 2

2014 European Medicines Agency - EPARs

9. Mirvaso - brimonidine

Mirvaso - brimonidine 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. 19 December 2013 EMA/CHMP/115246/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Mirvaso International non-proprietary name: brimonidine (...) Procedure No. EMEA/H/C/002642/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment Report EMA/CHMP/115246/2014 Page 2/107 Product information Name of the medicinal product: Mirvaso Applicant: Galderma International Tour Europlaza, 20 avenue André Prothin – La Défense 4 La Défense Cedex 92927 France Active substance: Brimonidine tartrate International Nonproprietary Name: Brimonidine Pharmaco-therapeutic group (ATC Code): Other

2014 European Medicines Agency - EPARs

10. Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension)

Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) Drug Approval Package: SIMBRINZA (brinzolamide/brimonidine tartrate) NDA #204251 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension), 1%/0.2% Company: Alcon Research, Ltd Application No.: 204251 Approval Date: 04/19/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

2013 FDA - Drug Approval Package

11. Mirvaso (brimonidine) Topical Gel

Mirvaso (brimonidine) Topical Gel Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Mirvaso (brimonidine) Topical Gel Company: Galderma Research and Development Inc. Application No.: 204708 Approval Date: 8/23/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2013 FDA - Drug Approval Package

12. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review

The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review Hodge W G, Lachaine J, Steffensen I, Murray C (...) , Barnes D, Foerster V, Ducruet T, Morrison A CRD summary This review concluded that latanoprost was superior to dorzolamide but not brimonidine. However, fewer adverse events were found for latanoprost than brimonidine. The authors' conclusions follow from the data presented, but are based on small data sets and as such some caution is advisable. Authors' objectives To assess the efficacy and safety of prostaglandin analogues (PGAs) compared to brimonidine and dorzolamide in people with elevated

2008 DARE.

13. Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database

Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database Lafuma A, Laurendeau C, Berdeaux G (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the persistence and costs of brimonidine versus brinzolamide. The authors concluded that brinzolamide was more persistent than brimonidine, with patients

2008 NHS Economic Evaluation Database.

14. Brimonidine Tartrate Ophthalmic Solution

Brimonidine Tartrate Ophthalmic Solution Drug Approval Package: Brimonidine Tartrate NDA #021764 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Brimonidine Tartrate Ophthalmic Solution Company: Alcon, Inc. Application No.: 021764 Approval Date: 05/22/2006 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: February 22, 2008 Note: Documents in PDF format require the . - - Links on this page: Note: If you need help accessing

2006 FDA - Drug Approval Package

15. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension

An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular (...) hypertension Stewart W C, Leech J, Sharpe E D, Kulze J, Ellyn J, Day D G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The authors investigated a switch to latanoprost monotherapy, or the addition of latanoprost or brimonidine

2002 NHS Economic Evaluation Database.

16. Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model

Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model Switching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a model Abelson M B, Netland P A, Chapin M J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of brimonidine monotherapy for the treatment of patients with glaucoma or ocular hypertension. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised adult patients with a history

2001 NHS Economic Evaluation Database.

17. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma

Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma Einarson T R, Kulin N A, Tingey D, Iskedjian M Authors' objectives To indirectly quantify and compare the intraocular pressure (IOP)- lowering effects (...) of latanoprost and brimonidine eye drops at baseline and after 3 and 6 months in the treatment of primary open-angle glaucoma. Searching The authors searched MEDLINE and EMBASE (1992 to May 1999) using the search terms 'ophthalmic', 'glaucoma', 'clinical trial', and either 'latanoprost' or 'brimonidine'. References from the retrieved articles were searched for additional studies. The search was restricted to English language publications. Study selection Study designs of evaluations included in the review

2000 DARE.